Nov 4 (Reuters) – Sino Biopharmaceutical said on Wednesday it had entered into an option and license agreement with Germany’s Boehringer Ingelheim for six pre-clinical oncology programs that could generate about $7 billion in milestone payments.
(Reporting by Kumar Tanishk in Bengaluru)
Comments